{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003922","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.013161+00:00","generated_at":"2026-05-24T02:54:45.660580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML","bullets":["Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.","Cash and cash equivalents of $1.2M as of Dec 31, 2024; net cash used in operations $10.6M.","R&D expense decreased to $7.3M from $11.6M; G&A expense increased to $4.7M.","Preclinical BP1001-A shows restored insulin sensitivity; Phase 1/1b BP1002 in AML progressed to 90 mg/m² dose cohort.","Patent portfolio expanded: 7 US patents, 61 foreign patents; new patents in US and NZ."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003922","json":"https://secwatch.observer/filing/0001558370-25-003922.json","markdown":"https://secwatch.observer/filing/0001558370-25-003922.md","text":"https://secwatch.observer/filing/0001558370-25-003922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/0001558370-25-003922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025003922/bpth-20250328x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:54:45.660580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}